ConvaTec Group PLC
LSE:CTEC
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
213.4
293.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
ConvaTec Group PLC
ConvaTec Group PLC
Cash & Cash Equivalents
ConvaTec Group PLC
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ConvaTec Group PLC
LSE:CTEC
|
Cash & Cash Equivalents
$97.6m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Abingdon Health PLC
LSE:ABDX
|
Cash & Cash Equivalents
£3.2m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Tristel PLC
LSE:TSTL
|
Cash & Cash Equivalents
£4.8m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
1%
|
CAGR 10-Years
11%
|
|
|
Inspecs Group PLC
LSE:SPEC
|
Cash & Cash Equivalents
£20.1m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
|
Advanced Medical Solutions Group PLC
LSE:AMS
|
Cash & Cash Equivalents
£134.9m
|
CAGR 3-Years
30%
|
CAGR 5-Years
16%
|
CAGR 10-Years
29%
|
|
|
Cambridge Nutritional Sciences PLC
LSE:CNSL
|
Cash & Cash Equivalents
£2.9m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ConvaTec Group PLC
Glance View
ConvaTec Group PLC is a global medical technology company that specializes in the development and marketing of advanced products for wound care, ostomy care, continence care, and critical care. Founded in 1978 and headquartered in the UK, ConvaTec has established itself as a leader in the healthcare space, relentlessly focusing on innovative solutions that enhance patient outcomes and streamline healthcare delivery. With a diverse portfolio of trusted brands such as AQUACEL® and Versiva®, the company provides essential products that cater to the needs of patients with chronic, acute, and complex wounds as well as those requiring ostomy care. The company's growth trajectory has been bolstered by strategic investments in research and development, positioning it as a pioneer in integrating cutting-edge technologies into its offerings. As an investor, ConvaTec presents a compelling opportunity driven by increasing demand in the healthcare sector, notably due to an aging population, rising prevalence of chronic conditions, and heightened awareness of infection control. The company has demonstrated resilience and adaptability in navigating market fluctuations, evidenced by its strong revenue growth and operational improvements. With a robust pipeline of innovative products and a commitment to sustainability, ConvaTec is well-positioned to capitalize on emerging trends in healthcare. As healthcare evolves, its focus on delivering high-quality solutions not only enhances patient experiences but also promises to yield solid returns for investors looking to support the future of medical innovation.
See Also
What is ConvaTec Group PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
97.6m
USD
Based on the financial report for Dec 31, 2023, ConvaTec Group PLC's Cash & Cash Equivalents amounts to 97.6m USD.
What is ConvaTec Group PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-21%
Over the last year, the Cash & Cash Equivalents growth was -32%. The average annual Cash & Cash Equivalents growth rates for ConvaTec Group PLC have been -44% over the past three years , -21% over the past five years .
You don't have any saved screeners yet
